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Plasma protein binding in uremia: Extraction and character-
ization of an inhibitor. The impairment of binding of drugs and
other substances to serum albumin in patients with uremia can be
restored to normal or near normal levels by adsorption with char-
coal or synthetic polymers at pH 3. We used a nonionic poly-
styrene-divinylbenzene copolymer to treat uremic plasma at pH
3. We observed a marked improvement of binding. Subsequent
elution of this resin with ethanol produced a substance that,
when dried and recombined with normal plasma, caused dose-
dependent impairment of phenytoin and tryptophan binding.
Restoration of normal binding affinity occurred after retreatment
of this abnormalized plasma with resin at pH 3. Plasma and
pleural fluid exudate from patients with uremia yielded, after ex-
traction by the above technique, an inhibitor(s) of phenytoin
binding in amounts averaging five times that extracted from
equal volumes of normal plasma. This inhibitor (I') is water sol-
uble, heat stable, and dialyzable across cellophane membranes.
Unlike fatty acids, which can also interfere with binding, I, parti-
tions primarily in the water phase in solvent partition studies but
undergoes a sharp transition in the pH 4 to 5 range, suggesting
the presence of a carboxyl group. These findings lend further
support to the hypothesis that a retained ligand(s) is responsible
for impaired plasma binding associated with uremia and suggests
a role for organic acids known to accumulate in renal failure.
Liaison aux protéines plasmatiques dans l'urémie: Extraction et
caractérisation d'un inhibiteur. L'altération de Ia liaison de
drogues et d'autres substances a l'albumine sérique au cours de
l'urémie peut étre complètement ou presque complètement sup-
primée par l'adsorption sur du charbon ou des polymères syn-
thétiques a pH 3. Nous avons utiisé un co-polymére non ionique
polystyrênedivinylbenzène pour traiter le plasma urémique a pH
3 et observe une amelioration importante de la liaison. L'élution
ultérieure de cette résine par l'éthanol produit une substance
qui, lorsqu'elle est séchée et recombinée avec du plasma nor-
mal, determine une alteration dose dépendante de Ia liaison de la
diphényl-hydantoine et du tryptophane. La récupération d'une
affinité de liaison normale a été obtenue après un nouveau traite-
ment du plasma par Ia rCsine a pH 3. Le plasma et le liquide
pleural de malades urémiques a donné, après extraction par Ia
technique ci-dessus, un inhibiteur(s) de la liaison de la phényl-
hydantoine en quantité cinq fois plus grande que celle extraite de
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volumes identiques de plasma normal. Cet inhibiteur (Ix) est sol-
uble dans I'eau, thermostable et dialysable a travers des mem-
branes de cellophane. A la difference des acides gras, qui
peuvent aussi interferer avec Ia liaison, I, passe dans la phase
aqueuse au cours des etudes de partition dans des solvants, mais
subit une transition brusque dans la gamme de pH 4 a 5, ce qui
suggére La presence d'un groupe carboxyle. Ces constatations
apportent des arguments supplémentaires a l'hypothèse selon la-
quelle un ligand (ou des ligands) retenus au cours de l'urCmie est
responsable de l'altération de Ia liaison plasmatique et suggCre
un role des acides organiques dont l'accumulation est connue
dans l'insuffisance rénale.
Extensive in vitro studies of plasma from patients
with renal failure have documented defective bind-
ing of many drugs and several endogenous sub-
stances [1, 2]. In patients with advanced uremia, the
degree of binding inhibition for some drugs is of suf-
ficient magnitude as to require modification of drug
administration. Much effort has been directed to-
ward identification of individual drugs whose bind-
ing in uremia is critically impaired, but relatively
few investigations have been devoted to uncovering
the nature and causes of this binding inhibition [3-
5].
Although several plasma proteins are known to
bind a variety of drugs and other substances, the
plasma protein that is most prominent in this role is
albumin. It is also clear that the reduced albumin
concentration, which is found especially in sympto-
matic uremic patients or poorly dialyzed patients,
contributes to, but is not the major cause of, im-
paired plasma binding in uremia [6, 7]. Reduced
binding is found in patients with renal failure when
compared with normal persons with equal albumin
concentrations. This binding defect has been postu-
lated to result either from alteration of the primary
structure of albumin or from accumulation of an un-
known solute that interferes with binding [3-5].
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Strong support for the latter hypothesis has come
from studies demonstrating normalization of bind-
ing of several ligands by modified uremic plasma.
Such normalization was achieved by Craig et al [5]
using charcoal adsorption and by us using anion ex-
change resin treatment [7], both techniques being
applied to plasma at pH 3.0. These agents may re-
move from uremic albumin a modifying ligand,
which is hydrolyzed, is more loosely bound, or is
more readily accessible at low pH. The last possi-
bility is suggested by the fact that albumin under-
goes a series of reversible configurational transfor-
mations between pH 3 to 4.5 [8]. The mechanism by
which charcoal or resin restores binding by uremic
plasma to normal has not been determined.
In this study we have attempted to recover inhib-
itory material from the resin used to normalize bind-
ing by uremic plasma. Because it has been well
characterized for uremic plasma, we used binding
of phenytoin by normal plasma as the test system to
assay for inhibitory activity. By using a nonionic,
hydrophobic resin for adsorbing uremic plasma and
eluting it with ethanol, we obtained an extract con-
taining an inhibitor(s) of phenytoin binding. We
have determined a number of in vitro properties of
the resin extract, which is free of proteins, serum
electrolytes, and major small solutes.
Methods
Plasma was obtained from normal and hemodia-
lyzed subjects in the fasting state after full consent
was obtained according to the standards set forth by
the Human Rights Committee at the University of
California, Davis. Patients selected were stable out-
patients who had been dialyzed for 1 to 3 years,
ranged in age from 22 to 74 years, required a mini-
mum number of drugs, and most had not taken
drugs or caffeine for 48 hours prior to the venipunc-
ture. A large amount of pleural fluid was collected
from one hemodialyzed patient, who required ther-
apeutic thoracentesis on two separate occasions.
This fluid was drawn in both instances without anti-
coagulants while the patient was in the fasting state
and after drug abstinence as above. Heparinized
plasma and pleural fluid were stored at 70° C for
less than 3 months prior to use.
Albumin concentration. Plasma albumin concen-
tration of most samples was measured, as described
by Doumas, with bromcresol green (BCG) except
that readings were taken at 1 mm after mixing [9].
This method was evaluated previously and found to
give equivalent results in normal subjects and pa-
tients with renal failure [7].
Plasma binding of 14C-phenytoin and '4C-trypto-
phan. Binding of 14C-phenytoin by whole plasma or
purified albumin was measured by centrifugal ultra-
filtration with techniques previously described [3,
7]. When inhibitors of phenytoin binding were add-
ed to normal test plasma, the sensitivity of the assay
(to inhibition) was found to increase when the nor-
mal plasma was diluted 1:4 with isotonic 0.030 M
Tris buffer [7] prior to the assay. (The use of this
diluted assay is indicated in the text and figures.)
14C-tryptophan binding was measured in a similar
manner by using normal plasma diluted 1:4 with the
isotonic 0.030 M Tris buffer. 3-14C-L-tryptophan
(specific activity, 49,4 mCi/mM, from New England
Nuclear, Boston, Massachusetts) was added to the
diluted plasma to achieve a concentration of 0.05
jCi/m1. No unlabeled tryptophan was added.
Plasma '4C-tryptophan was measured after centrifu-
gation to compensate for slight binding of trypto-
phan to the cellophane bag.
Adsorption of uremic plasma with nonionized
resin. Plasma was acidified to pH 3, then passed
through resin columns as previously described [7],
except that in most studies, for reasons given in the
Results section, the uncharged XAD-2 polystyrene-
divinyl benzene copolymer, Biobeads® (from Bio-
Rad Laboratories, Richmond, California), was used
in place of the anion exchange resin. This hydro-
phobic resin was prepared prior to use by sequential
washing with 95% ethanol, distilled water, and 0.1 N
hydrochloric acid. initially, the effect of the un-
charged resin on binding by plasma was evaluated
in five pairs of normal and uremic subjects. With
gentle stirring and aeration, these plasma samples
were slowly acidified with 3 N hydrochloric acid to
pH 3. Aliquots were then set aside as acidified con-
trols. Approximately 12 to 14 ml of the remaining
plasma was passed at 3 mI/hr through 1 X 5-cm col-
umns (approximately 4.0 ml volume) of resin at
40 C, and 3-ml fractions were collected. The first
fraction, diluted with column water, and the second
fraction were discarded. The third and fourth col-
umn fractions and the acidified control were titrated
to pH 8.0 with small volumes of 3 N sodium hydrox-
ide, and, when necessary, the more concentrated
plasma of the pair was diluted with Tris buffer so
that each pair had the same final albumin concentra-
tion. Phenytoin was added to all samples, and bind-
ing was determined as described above for whole
plasma.
Elution of ligand-binding inhibitor from the resin.
The above columns were washed with water until
no precipitate formed in the wash after addition of
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trichloroacetic acid (TCA). Each column was then
washed with 10 to 30 ml of 100% ethanol. This ma-
terial subsequently will be referred to as the ethanol
eluate. The ethanol eluate was evaporated to dry-
ness under vacuum at room temperature by a rotary
evaporator. The dried residue was dissolved and in-
cubated at room temperature with 1.5 or 3.0 ml of
normal plasma. No pH changes were observed on
dissolving the residue with plasma. At least 50% of
the total binding inhibitory activity was found in the
first 10 ml of ethanol eluted from the column.
Isolation of inhibitor from large volumes of
plasma and pleural fluid. To further characterize
the inhibitor, we accumulated a pool of uremic
plasma from six donors, and large quantities of
pleural fluid were obtained from a single hemo-
dialyzed patient. The high protein content and re-
duced phenytoin binding of the pleural fluid sug-
gested to us that it might be a rich source of the
protein-bound inhibitor previously demonstrated in
uremic plasma. Solute content of the pleural fluid
was as follows: creatinine, 11.7 mgldl; bilirubin, 0.5
mg/dl; total protein, 5.6 g/dl; albumin, 3.0 g/dl. We
applied 100 to 300 ml of pooled plasma or pleural
fluid to larger columns (1.5 X 15cm, total volume 26
ml) containing XAD-2 resin as described above.
The columns were washed with distilled water until
protein was no longer detectable by TCA and were
then eluted with a volume of ethanol approximately
one-half to one-fourth the volume of plasma or
pleural fluid applied to the column. This ethanolic
solution was stored at 40 C for subsequent studies.
For dose-response assays, 0.3 to 12.0 ml of the etha-
nolic resin eluate was evaporated at room temper-
ature under vacuum. We added 3 ml of a pool of
normal plasma to each flask, mixed it at room tem-
perature with gentle agitation, and then incubated it
overnight at 40 C. After addition of phenytoin, bind-
ing was measured as above.
Characteristics of the inhibitor. Gravimetric anal-
ysis was done by the method of Kupke and Dorrier
[10] on the dried ethanol eluate, which was solubi-
lized by extraction with water. Solute content was
evaluated by Technicon SMAC 20-channel analysis
of a 0.5-mi sample of ethanol eluate that had been
dried and reconstituted with 1.0 ml of water. Dial-
ysis of the inhibitor was performed in 5-ml acrylic
plastic cells with a cellophane membrane (Spectra-
phor 2 membrane, Spectrum Medical Industries,
Inc., New York, New York; mol wt cutoff, 12,000
to 14,000 daltons). Two-milliliter samples of etha-
nolic eluate isolated from uremic plasma and pleural
fluid were evaporated and reconstituted in 5 ml of
water. These solutions were dialyzed against 5 ml of
distilled water on a rocker at 40 C overnight.
Samples from both sides of the membrane were
lyophilized, and the residues were dissolved with
normal plasma for analysis of binding inhibition as
described above. Heat stability of an aqueous solu-
tion of the inhibitor was studied at pH 3.3 and 10.
Two 4-mi samples of ethanol column wash were
evaporated and reconstituted with 4 ml of water.
The pH of the solution was 3.3. One 4-ml sample
was titrated to pH 10.0 with 0.1 N sodium hydro-
xide. Both samples were incubated at 100° C for 30
mm. These samples and unheated controls were
then lyophilized and dissolved with normal plasma.
Binding of phenytoin was measured as above.
Fluorescence excitation and emission spectra were
obtained with a spectroflurometer (Farrand Mark I).
Solvent partition studies were performed to de-
termine the lipid solubility of inhibitory activity as a
function of pH. Aliquots of the ethanol extract were
dried, dissolved in distilled water, and titrated with
hydrochloric acid or sodium hydroxide to pH val-
ues from 1.0 to 10. These aqueous solutions of in-
hibitory activity were added to equal volumes of
ethylene dichioride or diisopropyl ether in separa-
tory funnels and mixed vigorously. The phases
were allowed to separate overnight at 40 C. The
aqueous and organic phases were separated, dried,
combined with normal test plasma, and binding of
phenytoin was assayed in the samples and controls
without inhibitor. The simultaneous partitioning of
l-'4C-oleic acid (54 mCilmmole; Amersham, Arling-
ton Heights, Illinois) was determined in a similar
fashion, except that the 14C-oleic acid was dried and
dissolved in the organic phase before being mixed
with aqueous solutions of the inhibitor, titrated as
described above.
Results
We previously used anion exchange resin AG1-
X8 from Bio-Rad Laboratories to normalize bind-
ing. After this resin was exposed to uremic plasma,
several attempts were made to remove an inhibitor
from it by eluting with hydrochloric acid at concen-
trations up to 200 mrvi, 200 mri ammonium hydrox-
ide, and 100% ethanol. Failing in these attempts, we
turned to a nonionic copolymer of styrene and divi-
nyl benzene, XAD-2, which like AG-i also pro-
duced effective improvement of phenytoin binding
in uremic plasma. Table 1 shows phenytoin binding
of five pairs of uremic and normal plasma studied
after acidification alone and after resin treatment.
The ratio of percent phenytoin unbound for each
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Table 1. Effect of acid-resin treatment on phenytoin binding by normal and uremic plasmaa
Acidified control Acid-resin treated
UnboundUnbound
Study
Albumin
Status gIdi
phenytoin
Albumin
g/dl
phenytoin
% Ratio U/N % Ratio U/N
1 U 4.54
N 4.48
23.0
16.3 1.41
4.37
4.40
18.5
16.8 1.10
2 U 2.80
N 2.90
27.3
20.2 1 35•
3.03
2.84
19.6
18.0 1.09
3 U 3.79
N 3.80
27.2
19.0 1 43•
3.80
3.79
20.5
18.5 1.11
4 U 3.78
N 3.87
29.7
19.9 1 49
3.82
3.79
24.5
20.6 1.19
5 U 4.44
N 4.22
23.7
16.1 1 47
4.31
4.23
18.2
16.0 1.14
Mean 1.43 1.13
SEM 0.02 0.02
Significance (paired difference) P <0.001
Significance (vs. 1.00) P <0.001 P <0.001
a U denotes uremic plasma; N, normal.
uremic/normal pair improved significantly, from
1.43 after acidification alone to 1.13 after the acid-
ified plasma was passed through the resin. The im-
provement of binding was similar to our previous
findings with the AG-I anion exchange resin [7].
Elution of inhibitor. When the dried ethanol
eluate from the resin was combined with normal
plasma, significant impairment of phenytoin binding
by normal plasma resulted. Ethanol eluates from
resin columns exposed to normal plasma produced
a small but significant decrease in binding of 3.3
0.8% (Table 2), possibly due to inhibitors present in
and subsequently removed from normal plasma by
the resin. The resin that had been exposed to ure-
mic plasma, however, yielded much larger quan-
tities, averaging 5.4 2.5 times the amount in the
normal plasma. Ethanol blank eluates from resin
that had not been exposed to plasma yielded no ap-
preciable inhibitory activity.
Dose-response relationship. We examined the
relationship between the amount of plasma or pleu-
ral fluid and the degree of binding inhibition
achieved by incubating a constant volume of normal
plasma with varying quantities of the ethanol ex-
tract. A curvilinear relationship between response
and the volume of pleural fluid extracted indicates a
plateau in the effect of the inhibitor at higher con-
centrations (Fig. 1). Absolute binding by undiluted
normal plasma combined with the inhibitor dropped
from 87% to approximately 60% and appeared to
approach a plateau at that level or slightly below.
Phenytoin binding by the pleural fluid used in
these studies (albumin concentration, 3.0 g/dl) was
Table 2. Inhibition of phenytoin binding by dried ethanol eluate
from resins that adsorbed normal or uremic plasma"
Decrement5
Phenytoin
Study Samples
bound
% %
Ratio
RU/RN
I PN
RN
RU
87.6
84.9
76.3
2.7
11.3 4.2
2 PN
RN
RU
86.3
81.2
63.2
5.1
23.1 4.5
3 PN
RN
RU
88.4
83.1
77.5
5.3
10.9 2.0
4 PN
RN
RU
88.5
86.7
78.3
1.8
10.2 5.7
5
Mean
PN
RN
RU
87.9
86.1
69.6
1.8
18.3 10.2
5.3
ap denotes normal test plasma; RN, normal test plasma
combined with elute from XAD-2 resin exposed to normal
plasma; RU, normal plasma combined with eluate from XAD-2
resin exposed to uremic plasma.
Decrements are the differences between PN and RN, and be-
tween PN and RU. The mean SCM decrements were: RN, 3.3
0.8%; RU, 14.8 2.5%
68 to 70% at 370 C and improved by 5 to 6% after
resin treatment. Binding by plasma from this same
patient (albumin concentration, 3.32 gldl) was
72.1% at 37°C.
Reversibility. The "synthetic uremic plasma"
produced by combining normal plasma with eluate
from resin previously exposed to uremic plasma
C
a,
E
•0
C0
££
% Phenytoin bound
was treated with anion-exchange resin at pH 3 to
test the important question of whether the induced
inhibition was reversible, as in uremic plasma, or
was a nonspecific, irreversible effect. Table 3 shows
that complete normalization was achieved as occurs
for natural, uremic plasma [7], a finding which sup-
ports the concept that a retained substance(s) is re-
sponsible for inhibition of ligand binding in uremia.
Specificity of binding inhibition. In Table 4 the
inhibitory effect is shown not to be unique to pheny-
tom binding and in this respect resembles uremic
plasma itself, which exhibits decreased binding to a
number of drugs and other substances including
tryptophan [2, 3].
In addition, plasma from other animal sources
and purified human albumin preparations, which
vary in their affinity for phenytoin, are affected by
the resin eluate (Table 5). Of note is the poor bind-
ing by isolated human albumin of 15% to 35% com-
pared with around 60% for equally diluted normal
plasma at 37° C. The pure albumin preparations
used here were isolated by different techniques, in-
A. Untreated normal plasmaa 56.0
B. Plasma and inhibitor 30.7
C. Acidified only 38.8
D. Acidified and resin treated 54.0
° SampleA was an untreated diluted normal plasma. Sample B
(the same plasma as sample A) was used to dissolve one half
volume of dried ethanol eluate containing uremic inhibitor.
Sample C was equivalent to sample B but had been acidified to
pH 3.0 and then titrated back to pH 8.0 before phenytoin binding
was tested. Sample D was treated as was sample C except that it
was passed over an AG-I column at pH 3.0 and then titrated
back to pH 8.0. All studies were done with plasma diluted 1:4
with isotonic Tris buffer (see Methods).
Table 4. Effect of inhibitor on tryptophan bindinga
Ethanol eluate added"
ml
Tryptophan bound
%
Inhibition
%
0 49.5 —
0.5 32.9 —16.6
1.0 24.3 —25.2
2.5 18.4
—31.1
° All binding measurements were done with 1.5 ml of a normal
plasma after 1: 4 dilution with Tris buffer (see Methods).
Eluate was evaporated to dryness before being dissolved
with the diluted plasma (see Methods).
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cluding alcohol and salt fractionation and affinity
40
chromatography.
Solvent partitioning and other characteristics of
• • the inhibitor. Relative solubility in organic com-
pared with aqueous solvents was examined by par-
titioning of an aqueous buffered solution of the in-
30 hibitor with an equal volume of ethylene dichioride
• U or diisopropyl ether. Partitioning into the organic
• phase increased as pH was lowered (Fig. 2). There
was a change of partitioning in the range of pH 4 to
£ 5, the inhibitor being totally in the aqueous phase£ above pH 5.0, but 15 to 33% being in the organic
-20 phase below pH 4.0.
For reasons discussed below a similar partition-
a ing was carried out with the most abundant plasma
A fatty acid, oleic acid [131. In contrast with the ure-
mic plasma extract, oleic acid is much more soluble
• in the organic phase over the pH range 3 to 10. The
percentage of total 14C-oleic acid in ethylene dichlo-£ ride ranged from 99.1% at pH 3 to 96.0% at pH 6.5.
Partitioning of 14C-oleic acid between diisopropyl
ether and an aqueous solution (data not shown)
showed 99.1% and 93.2% of the carbon 14 in the
I I I I organic phase at pH 3 and 10, respectively.
10 20 30 40 50 60 70 Titration of the crude extract from pH 2 to 10
Plasma or pleural fluid volume, ml with 0.2 N hydrochloric acid revealed significant
Fig. 1. Dose-response relationships for inhibitor of plasma phe- buffering in the 3 to 5 pH range, adding further evi-
nytoin binding extracted from uremic plasma (•) or uremic
pleural fluid (•, A). The normal test plasma for each dose-re-
sponse series was used either undiluted (•, A) or after 1 : 4 dilu- . . .
tion (U). Table 3. Reversibihty of phenytoin binding inhibitions
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Table 5. Effect of inhibitor on phenytoin binding by plasma from various species and on purified human albumina
Type of specimen"
Albumin
gidi
14C-phenytoin bound
%
Inhibition
%
Bovine plasma
Undiluted 4.07 83.5
Diluted
Diluted + inhibitor
1.07
1.07
45.3
35.0 —10 3.
Ovine plasma
Undiluted 3.09 83.6
Diluted
Diluted + inhibitor
1.00
1.00
49.3
35.7 —13 6.
Equine plasma
Undiluted 3.42 59.5
Diluted
Diluted + inhibitor
0.92
0.92
23.4
15.4 —8 0
Human albumin A
Alone
+ Inhibitor
0.89
0.89
18.6
7.6 11 0.
Human Albumin B
Alone
+ Inhibitor
0.90
0.90
34.5
3.0 —31 5.
Human Albumin C
Alone
+ Inhibitor
0.88
0.88
15.1
0 —15 1.
Human Albumin D
Alone
+ Inhibitor
0.86
0.86
28.9
6.1 —22 8.
a Source of inhibitor was 1.0 ml of ethanol eluate, derived from 4.0 ml of uremic pleural fluid, dried and combined with 1.5 ml of plasma
or albumin solution. Plasma samples were diluted with Tris buffer (see methods). Albumins were dissolved in water.
The human albumins were: A, Sigma fraction V; B, Sigma fraction V, fatty acid free; C, Sigma fraction V, crystalized and lypophi-
lized; D, Albumin from Calbiochem prepared by affinity chromatography.
dence that an acidic group with a pK of 4 to 5 is a
component of the inhibitor. Other characteristics of
the crude ethanol eluate that contains the inhibitor
are listed in Table 6. When the ethanolic elute is
evaporated and the residue is extracted with water,
the water extract contains all of the binding inhib-
itory capacity. This water extract had no detectable
sodium, potassium, chloride, urea, creatinine, bili-
rubin, uric acid, phosphorus, calcium, glucose, or
cholesterol. When this protein-free water extract of
the ethanol elute was dialyzed against an equal vol-
ume of water across a cellophane membrane with a
mol wt cutoff of 12,000 to 14,000 daltons, the inhib-
itory activity was equal in the two compartments
after 16 hours of dialysis. Gravimetric analysis of
the lyophilized aqueous extract of the ethanol elute
yielded a weight of approximately 0.35 mg/mi of
pleural fluid extracted. There is no loss of activity
when an aqueous solution is heated at 1000 C for 30
mm at pH 3 and 10. Fluorescence of the aqueous
extract is observed with an excitation peak at 340
mt and an emission peak at 420 mp
using charcoal, both at pH 3.0, proved that im-
paired binding of small organic ligands by uremic
plasma proteins was a reversible defect and, there-
fore, not the result of irreversible damage to the
binding protein by some aspect of the uremic state
[4, 5, 7]. The failure of both in vivo and in vitro
dialysis to correct this binding abnormality [3, 5]
suggested several possible mechanisms that could
lead to this abnormality.
Having failed to elute from the anion exchange
resin, AG-i, material that would reduce binding of
small ligands' by normal plasma, we tested the abil-
ity of the nonionic core of the AG-i resin, that is,
the polystyrene/divinyl-benzene resin XAD-2, to
correct the defective binding of uremic plasma. This
type of resin is known to strongly adsorb organic
compounds from aqueous solution and fatty acids
from acidified plasma [ii, 14]. Table 1 shows that
the XAD-2 resin produced almost as much improve-
ment in binding by uremic plasma as did AG-i fol-
lowing acidification alone and acidification plus res-
Discussion
Our previous studies on treating uremic plasma
with an anion exchange resin and studies by others
'Unless otherwise stated, the ligands to which we refer is the
group of acidic, aromatic ligands, which are bound less avidly by
uremic than normal plasma (for example; tryptophan, phenytoin,
salicylate, warfarin, phenylbutazone).
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1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0
pH (at 25° C(
Fig. 2.Partitioning between distilled water solution andethylene
dichioride of inhibitors activity (A, •) and of added 14C-oleic
acid (0). Inhibitory activity was extracted either from uremic
pleural fluid (0, A) or from uremic plasma (•).
in treatment. In previous studies using AG-i, the
ratios of percent unbound phenytoin for uremic to
normal plasma were 1.43 for the acidified control
and 1.08 for the acid-resin treated group [7].
An ethanol wash of the XAD-2 resin column
yielded a crude extract, which was a potent inhib-
itor of phenytoin binding by normal plasma. The
early, nearly linear portion of the dose response
curves (Fig. 1) can be used to quantitate the content
of inhibitor in biologic fluids. It should be noted also
that the sensitivity of the assay was nearly doubled
when test plasma that had been diluted 1:4 was
used. That the inhibitory material is not unique to
uremic fluids is shown in Table 2; extracts from nor-
mal plasma produce about 20% as much inhibition
as extracts of uremic plasma.
The specificity of the inhibitory extract was test-
ed in several ways. The extract produced a dose-
dependent inhibition of tryptophan binding, an ab-
normality characteristic of uremia [3]. Limited data
suggests that albumin is the major binding protein
for these acidic/aromatic ligands [15]. The inhibitor
was active against four different pure preparations
of commercial albumin (Table 5). It is noteworthy
that none of these albumin preparations bound
phenytoin as effectively as did normal plasma con-
taining an equivalent concentration of albumin. In
35 control studies, whole plasma diluted 1:4 has
shown 52% to 67% binding of "C-phenytoin. It is
possible that other plasma proteins do, in fact, also
bind phenytoin or that the purified albumins have
been subtly altered during the purification process.
Finally, there may be cofactors in plasma that are
necessary for optimum binding but are removed
during purification [16].
That albumins from different animal species have
different primary structures is well established [8].
They also show different binding properties. Be-
cause it would be very useful to be able to use ani-
mal plasma in future studies because of the large
volume of plasma required in many studies planned,
we tested the effect of the inhibitory extract on
plasma from three large animals. As seen in Table 5,
a good effect was produced on bovine, ovine, and
equine plasma.
A number of properties of the inhibitory com-
ponent in the crude ethanol extract have been deter-
mined. At the time these studies were begun, we
regarded plasma free fatty acids to be highly likely
candidates as the inhibitor. They are extremely
tightly bound to plasma albumin at pH 7.4, they dis-
place many albumin-bound ligands, and they can be
totally removed at pH 3.0 by adsorption with char-
coal or AG-l resin [11, 12]. The complete water sol-
ubility of the inhibitory component of the crude eth-
anol extract and its behavior on solvent partitioning
(Fig. 2) show that it is not a long-chain fatty acid.
This conclusion agrees with the finding of both nor-
mal total concentrations of free fatty acids and a
normal pattern of individual long-chain fatty acids
in uremic plasma [13, 17].
That the inhibitor is not a very large molecule
(that is,> 10,000 daltons) is shown by its ready pas-
sage across cellophane from an aqueous, protein-
free solution. Its stability in strong acid and alkali
and at high temperature will greatly simplify future
Table 6. Properties of a crude preparation of binding inhibitor
Concentration of water-solubilized extract/mI pleural fluid, mg/mI 0.35
Solubility in water, mg/mi 6
Odor Foul
Color Yellow-brown
Heat stability Aqueous solution stable at 100° C x 30 mm at pH 3 and 10
Dialyzability Completely equilibrates across cellophane in 16 hr
Fluorescence excitation maximum, ms 340
Fluorescence emission maximum, ins 420
0
:3
a.C,
0
0C
0
1.0
0.9
0.8
0.7
0.6
0.5
0.4
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attempts at isolation and purification. Because the
material at this stage is quite crude, we cannot de-
termine whether the strong fluorescence is due to
the inhibitor or a contaminant. Recently, it has been
shown that uremic plasma is abnormally fluores-
cent, and it is quite interesting that this fluorescence
moves with albumin on electrophoresis [18]. The
yellow-brown color and foul odor both are sugges-
tive of retained substances normally present in
urine. Finally, its adsorption to the XAD-2 resin
suggests that it has a hydrophobic component and
perhaps binds in part to albumin by hydrophobic in-
teraction. It does appear also to have, however, a
polar component including an ionizing group, per-
haps a carboxyl group, with a pK of 4 to 5 (Fig. 2).
Organic acids are retained in uremia [19].
Although the ethanol extract is clearly quite
crude, the total mass of material requiring further
purification is quite small. Of roughly 66.8 mg of dry
weight per milliliter of the pleural fluid extracted,
the water extract of the ethanol eluate contained on-
ly 0.35 mg/mi, that is, 0.5% of the starting solid. In
future studies we will optimize efficiency of recov-
ery of inhibitory activity up to this step, which we
roughly estimate to be 25% with the present meth-
od.
The nature of the interaction of the inhibitor and
plasma binding protein cannot be stated. In the
present study and the studies by Sjoholm and by
Craig [4, 5] a very low pH was required to normal-
ize binding by uremic plasma. Our previous study
of tryptophan binding showed normal tryptophan
binding by albumin isolated from uremic plasma by
salting out globulins with concentrated ammonium
sulfate and DEAE-Sephadex chromatography.
Thus, unfolding of albumin induced by both of these
treatments seems to be a requirement to remove the
inhibitor, perhaps by exposing bound inhibitor to
the adsorbent resin. Alternatively, these maneuvers
may displace an extremely tightly bound ligand
from plasma proteins. Finally, it is possible that the
inhibitor is covalently linked to protein at pH 7.4
with an acid labile bond. Covalently modified pro-
teins are known to occur after prolonged exposure
to glucose and aspirin [20, 21]. Boobis has recently
reported finding abnormal amino acid composition
and isoelectric focusing patterns for albumin isolat-
ed from uremic patients [22]. We cannot state at
present whether our results and hers are inter-
related. Purification of the inhibitor to homogeneity
appears quite feasible and should allow us to deter-
mine the precise nature of the interaction between
single plasma proteins and the inhibitor.
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